Nav: Home

New ways to measure solid stress in tumors could lead to improved understanding, therapies

November 28, 2016

Massachusetts General Hospital (MGH) investigators have developed new methods for mapping and measuring solid stress - the force exerted by solid and elastic components - within tumors, an accomplishment that may lead to improved understanding of those forces and their consequences and to novel treatment strategies. The team from the Steele Laboratories of Tumor Biology in the MGH Radiation Oncology Department report their findings in the inaugural issue of Nature Biomedical Engineering.

"It has long been known that tissue stiffness is higher than normal in fibrotic tumors - tumors containing significant amounts of collagen and other connective tissues - and that has been linked to several hallmarks of cancer, including tumor growth, invasiveness and metastasis," says Rakesh K. Jain, PhD, director of the Steele Laboratories and corresponding author of the paper. "Solid stress is different from stiffness: It is the mechanical force transmitted within fibrotic tumors, and like a compressed spring, it accumulates and is stored as elastic energy within a tumor as it grows."

Jain's team discovered the first evidence of solid stress in tumors in 1997 and provided the first measurements in 2012. In numerous studies they have shown that the compression of blood and lymphatic vessels by solid stress contributes to tumor progression by impairing the supply of oxygen, which reduces the effectiveness of chemotherapy, immunotherapy and radiation treatment. More recently they found that the application of solid stress to tumors in living animals directly stimulates pathways involved in the initiation and migration of tumors. Strategies to alleviate solid stress by reducing collagen and hyaluronic acid, two primary structural components of the extracellular matrix that carry stress, have led to new approaches to enhancing the results of conventional therapies, which are currently being tested in an MGH clinical trial.

The Nature Biomedical Engineering paper describes the team's development of experimental and mathematical frameworks providing two-dimensional mapping of solid stress in tumors; sensitive estimation of the low levels of solid stress within small tumors, such as metastases; and the ability to quantify solid stress in tumors in living animals. All these methods were based on the concept of cutting the tumor and, as the stresses stored during tissue growth are released, high-resolution measurement of the tissue deformation with ultrasound or optical microscopy.

Using these methods to make measurements in mouse models of both primary and metastatic tumors, as well as in a few human tumor samples, revealed that solid stress and stored elastic energy may be different in primary and metastatic tumors, since they depend on both tumor cells and the surrounding microenvironment. Tumors with higher elastic energy are not necessarily stiffer, and vice versa; solid stress increases as tumors grow larger, and the normal tissue surrounding a tumor contributes significantly to solid stress.

"Two drugs are now in clinical trials based on their ability to release the mechanical forces exerted on tumor blood vessels by targeting collagen and hyaluronic acid," says Jain, who is the Cook Professor of Radiation Oncology (Tumor Biology) at Harvard Medical School. "Similar to the methods we previously developed to measure solid stress, these new methods could also be used to measure the results of solid-stress-reducing agents."

He adds, "The characterization of solid stress would also be beneficial in treatment of cancer in obese patients. We recently found that cooperation between fat cells, immune cells and fibroblasts in pancreatic tumors exacerbates the fibrotic microenvironment in obese patients, further promoting blood vessel compression. This is probably the most significant consequence of solid stress identified to date, and characterizing the response to agents designed to alleviate solid stress could improve the dismal outcomes of this often-deadly cancer."
Hadi T. Nia, PhD, of the Steele Labs is lead author of the Nature Biomedical Engineering report. Additional co-authors are Hao Liu, MD, Giorgio Seano, PhD, Meenal Datta, Dennis Jones, PhD, Nuh Rahbari, MD, Joao Incio, MD, PhD, Vikash Chauhan, PhD, Keehoon Jung, PhD, John Martin, PhD, Vasileios Askoxylakis, PhD, Timothy P. Padera, PhD, Dai Fukumura MD, PhD, Yves Boucher, PhD, and Lance L. Munn, PhD, Steele Labs; Francis Hornicek, MD, PhD, MGH Orthopædic Surgery; Alan J. Grodzinsky, ScD, Massachusetts Institute of Technology; and James W. Baish, PhD, Bucknell University.

Support for the study includes National Institutes of Health grants P01-CA080124 and R01-HL128168, National Cancer Institute Outstanding Investigator Award R35-CA197743, and Department of Defense Breast Cancer Research Innovator Award DP2 OD008780. The MGH has filed a patent application based on the methods described in this paper.

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The MGH Research Institute conducts the largest hospital-based research program in the nation, with an annual research budget of more than $800 million and major research centers in HIV/AIDS, cardiovascular research, cancer, computational and integrative biology, cutaneous biology, human genetics, medical imaging, neurodegenerative disorders, regenerative medicine, reproductive biology, systems biology, photomedicine and transplantation biology. The MGH topped the 2015 Nature Index list of health care organizations publishing in leading scientific journals and earned the prestigious 2015 Foster G. McGaw Prize for Excellence in Community Service. In August 2016 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Listen Again: The Power Of Spaces
How do spaces shape the human experience? In what ways do our rooms, homes, and buildings give us meaning and purpose? This hour, TED speakers explore the power of the spaces we make and inhabit. Guests include architect Michael Murphy, musician David Byrne, artist Es Devlin, and architect Siamak Hariri.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

What If?
There's plenty of speculation about what Donald Trump might do in the wake of the election. Would he dispute the results if he loses? Would he simply refuse to leave office, or even try to use the military to maintain control? Last summer, Rosa Brooks got together a team of experts and political operatives from both sides of the aisle to ask a slightly different question. Rather than arguing about whether he'd do those things, they dug into what exactly would happen if he did. Part war game part choose your own adventure, Rosa's Transition Integrity Project doesn't give us any predictions, and it isn't a referendum on Trump. Instead, it's a deeply illuminating stress test on our laws, our institutions, and on the commitment to democracy written into the constitution. This episode was reported by Bethel Habte, with help from Tracie Hunte, and produced by Bethel Habte. Jeremy Bloom provided original music. Support Radiolab by becoming a member today at     You can read The Transition Integrity Project's report here.